Biospecimen Marketplace

The supply chain
research has been
waiting for.

Helio matches researchers with pre-qualified donors through AI-powered profiling. Faster sourcing. Lower costs. Ethically compensated donors.

Become a donor For researchers
$7–12B
Market size
60–75%
Gross margin
$300–500
Per specimen
<30s
AI match time

How Helio works

A pure marketplace model. We never touch blood. Partner clinics draw, academic labs process, couriers ship.

1

Donors enroll

Donors join through Helio Rewards. They share their health profile anonymously and get matched to studies that need their specific biology.

2

AI matches specimens

Our matching engine pairs donor profiles with researcher requirements in under 30 seconds — replacing weeks of manual CRO recruitment.

3

Partner clinics collect

Donors visit a local partner clinic for a quick draw. Specimens are processed by academic core labs and shipped directly to researchers.

Two brands. One mission.

Donors earn. Researchers discover. Helio connects them.

Why Helio

The biospecimen market is broken. We're fixing the supply side.

Never touches blood

Pure marketplace — like Uber for biospecimens. Partner clinics draw, academic core labs process, couriers ship. Near-zero fixed costs.

Owns the supply

Direct-to-donor recruitment through Helio Rewards. No intermediary. No CRO markup. Donors come to us because we pay them fairly.

AI-powered matching

Donor health profiles matched to study requirements in seconds. Replaces manual recruitment that takes weeks and costs thousands per specimen.

Ethically aligned

Donors are celebrated, not extracted. Fair compensation, full anonymity, HIPAA compliance. Science should give back to the people who power it.

The sun doesn't ask
for anything in return.

It just gives — and everything lives because of it. Donors are the same. They are the source. Research orbits around them.

Helio exists to celebrate the people who let science move forward — and make sure they're rewarded for it.

Partner with Helio

Research facilities, clinical partners, and investors.

Get in touch